Continuously taking these medicines may double the risk of stomach cancer

Share This Post

A study published in “Intestine” showed that long-term use of proton pump inhibitors will double the risk of gastric cancer . Proton pump inhibitors are a class of drugs used to treat gastric acid reflux. ,

Continuous use of this drug will eliminate Helicobacter pylori, which is closely related to the development of gastric cancer. In general, eliminating H. Helicobacter in the intestine can significantly reduce the risk of stomach cancer. But a considerable proportion of people still continue to develop gastric cancer. According to statistics, in recent years, gastric cancer has become the third leading cause of cancer death in the world.

Previously published research found a relationship between the use of proton pump inhibitors and increased risk of gastric cancer, but scientists have not been able to prove the potential role of H. pylori itself. In this study, scientists tried to bypass this problem. They compared the data of participants who used proton pump inhibitors with another type of drug. The first group of participants was the proton pump inhibitor group, and the second group of participants The data comes from the data of participants using histamine H2 receptor antagonists, which are a class of drugs used to inhibit acid production. The investigators followed them up for 7.5 years.

During this time, the researchers observed that although both groups of participants had chronic gastritis, the group using proton pump inhibitors doubled their risk of stomach cancer during the study period, while taking H2 receptors blocked Participants did not have high-risk changes. In addition, the researchers also found that more frequent use will bring greater risks, and daily use will increase the risk of gastric cancer by more than four times.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy